The Motley Fool recommends Abbott Laboratories stock for dividend reliability and growth
Updated
Updated · The Motley Fool · Apr 28
The Motley Fool recommends Abbott Laboratories stock for dividend reliability and growth
4 articles · Updated · The Motley Fool · Apr 28
Abbott Laboratories has declared 399 consecutive quarterly dividends since 1924 and increased payouts for 54 straight years, with a current yield of 2.8%.
The company reported nearly 8% year-over-year revenue growth and 6% EPS growth in Q1, aided by acquisitions like Exact Sciences, and maintains a forward P/E ratio of 16.6.
Amid war, tariffs, and global economic uncertainty, Abbott’s diversified business and status as a Dividend Aristocrat make it attractive for investors seeking stability and consistent returns.
Can Abbott's 54-year dividend streak survive its $23B acquisition and a recent profit forecast cut?
Can Abbott win the $60 billion cancer diagnostics race after its massive acquisition of Exact Sciences?
Is Abbott's stock a true safe haven, or is its low valuation a sign of hidden market risks?
As hospitals face a financial crisis, can Abbott maintain its strong sales growth in medical devices?
Will Abbott's new AI-driven biowearables and diagnostics actually lower healthcare costs for patients?
How might the recent Similac lawsuit and FreeStyle sensor recall damage Abbott’s long-term brand trust?